[{"indications": "Indications\u00a0hypertension (see also notes above)", "name": "OLMESARTAN MEDOXOMIL With diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "OLMESARTAN MEDOXOMIL", "With diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like\r\nsymptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria,\r\nhyperuricaemia; arthritis, musculoskeletal pain; less commonly angina, vertigo, rash; very rarely headache, thrombocytopenia,\r\nmyalgia, pruritus, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129688.htm", "doses": ["Initially 10\u00a0mg once daily; if necessary increased to\r\n20\u00a0mg once daily; max. 40\u00a0mg daily", "Name[Olmetec Plus\u00ae (Daiichi Sankyo)  ] Tablets, f/c, olmesartan medoxomil\r\n20\u00a0mg, hydrochlorothiazide 12.5\u00a0mg (red-yellow), net price 28-tab\r\npack = \u00a312.95; olmesartan medoxomil 20\u00a0mg, hydrochlorothiazide 25\u00a0mg\r\n(pink), 28-tab pack = \u00a312.95; olmesartan medoxomil 40\u00a0mg, hydrochlorothiazide 12.5\u00a0mg (red-yellow), 28-tab pack = \u00a317.50"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension (see also notes above)", "name": "OLMESARTAN MEDOXOMIL With calcium-channel blocker", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "OLMESARTAN MEDOXOMIL", "With calcium-channel blocker"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like\r\nsymptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria,\r\nhyperuricaemia; arthritis, musculoskeletal pain; less commonly angina, vertigo, rash; very rarely headache, thrombocytopenia,\r\nmyalgia, pruritus, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202473.htm", "doses": ["Initially 10\u00a0mg once daily; if necessary increased to\r\n20\u00a0mg once daily; max. 40\u00a0mg daily", "Name[Sevikar\u00ae (Daiichi Sankyo)  ] Tablets 20/5, white, f/c, olmesartan\r\nmedoxomil 20\u00a0mg, amlodipine (as besilate) 5\u00a0mg, net price 28-tab pack\r\n= \u00a316.95\nTablets 40/5, ivory, f/c, olmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 5\u00a0mg, net\r\nprice 28-tab pack = \u00a316.95\nTablets 40/10, brownish-red, f/c,\r\nolmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 10\u00a0mg, net price\r\n28-tab pack = \u00a316.95"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension (see also notes above)", "name": "OLMESARTAN MEDOXOMIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "OLMESARTAN MEDOXOMIL"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like\r\nsymptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria,\r\nhyperuricaemia; arthritis, musculoskeletal pain; less commonly angina, vertigo, rash; very rarely headache, thrombocytopenia,\r\nmyalgia, pruritus, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127966.htm", "doses": ["Initially 10\u00a0mg once daily; if necessary increased to\r\n20\u00a0mg once daily; max. 40\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}, {"indications": "Indications\u00a0hypertension (see also notes above)", "name": "OLMESARTAN MEDOXOMIL With calcium-channel blocker and diuretic", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.2 Angiotensin-II receptor antagonists", "OLMESARTAN MEDOXOMIL", "With calcium-channel blocker and diuretic"], "cautions": "Cautions\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nCautions\u00a0Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal Effects under ACE Inhibitors, section 2.5.5.1). Monitoring of plasma-potassium concentration is advised, particularly in the elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients. Angiotensin-II receptor antagonists should be used with caution in aortic or mitral valve stenosis and in hypertrophic cardiomyopathy. Those with primary aldosteronism, and Afro-Caribbean patients (particularly those with left ventricular hypertrophy), may not benefit from an angiotensin-II receptor antagonist. Interactions: Appendix 1 (angiotensin-II receptor antagonists).", "side-effects": "Side-effects\u00a0see notes above; also gastro-intestinal disturbances;\r\nchest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like\r\nsymptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria,\r\nhyperuricaemia; arthritis, musculoskeletal pain; less commonly angina, vertigo, rash; very rarely headache, thrombocytopenia,\r\nmyalgia, pruritus, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/218764.htm", "doses": ["Initially 10\u00a0mg once daily; if necessary increased to\r\n20\u00a0mg once daily; max. 40\u00a0mg daily", "Name[Sevikar HCT\u00ae (Daiichi Sankyo)  ] Tablets 20/5/12.5, light orange,\r\nf/c, olmesartan medoxomil 20\u00a0mg, amlodipine (as besilate) 5\u00a0mg, hydrochlorothiazide\r\n12.5\u00a0mg, net price 28-tab pack = \u00a316.95\nTablets 40/5/12.5, light yellow,\r\nf/c, olmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 5\u00a0mg, hydrochlorothiazide\r\n12.5\u00a0mg, net price 28-tab pack = \u00a316.95\nTablets 40/10/12.5, greyish-red,\r\nf/c, olmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 10\u00a0mg, hydrochlorothiazide\r\n12.5\u00a0mg, net price 28-tab pack = \u00a316.95\nTablets 40/5/25, light yellow, f/c,\r\nolmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 5\u00a0mg, hydrochlorothiazide\r\n25\u00a0mg, net price 28-tab pack = \u00a316.95\nTablets 40/10/25, greyish-red, f/c,\r\nolmesartan medoxomil 40\u00a0mg, amlodipine (as besilate) 10\u00a0mg, hydrochlorothiazide\r\n25\u00a0mg, net price 28-tab pack = \u00a316.95"], "pregnancy": "Pregnancy\u00a0\n(From 2.5.5.2 Angiotensin-II receptor antagonists: British National Formulary)\nPregnancy\u00a0Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohydramnios have also been reported."}]